Amgen to take over Celgene’s OTEZLA for $13.4 billion; BMS increases share buyback

Discussion in 'Bristol-Myers Squibb' started by anonymous, Aug 26, 2019 at 1:26 PM.

  1. anonymous

    anonymous Guest

    Bristol-Myers-Squibb announced that Amgen will acquire Celgene’s Otezla business for $13.4 billion in a cash transaction. Bristol-Myers now expects to complete the pending merger with Celgene by the end of 2019. For More: